Dynavax Technologies (DVAX) - Stock & Dividends

Dynavax Technologies Corporation, traded as NASDAQ:DVAX, is a biopharmaceutical company in the commercial stage, with a primary focus on developing and bringing vaccines to the market in the United States.

One of its flagship products is HEPLISAV-B, a vaccine for hepatitis B that covers all known strains of the virus in individuals aged 18 years and above, available in both the United States and Europe. Additionally, Dynavax manufactures and sells CpG 1018, an adjuvant integral to HEPLISAV-B's efficacy.

Aside from its products, Dynavax Technologies Corporation has established collaborative agreements with various entities such as Valneva Scotland Limited, Zhejiang Clover Biopharmaceuticals, Inc., and several others, expanding its reach and capabilities in the biopharmaceutical industry.

Originally known as Double Helix Corporation, Dynavax Technologies Corporation has been in operation since 1996, with its headquarters situated in Emeryville, California. For more information, visit their website at https://www.dynavax.com.